DCGOHealthcare · Medical Care FacilitiesThe 5 Wall Street analysts covering DocGo, Inc. hold a median 12-month price target of $1.75 — +571.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 4 Nov 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores DocGo, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (10): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on DCGO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +571.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Sept 2026 | Needham | Reiterates | Buy | $3.00 |
| 18 Aug 2026 | Canaccord Genuity | Maintains | Hold | — |
| 18 Aug 2026 | Canaccord Genuity | Maintains | Hold | $1.00 |
| 18 Aug 2026 | Needham | Reiterates | Buy | — |
| 18 Aug 2026 | Needham | Reiterates | Buy | $3.00 |
| 25 Mar 2026 | Canaccord Genuity | Maintains | Hold | $1.50 → $1.00 |
| 25 Mar 2026 | Canaccord Genuity | Maintains | Hold | — |
| 17 Mar 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 17 Mar 2026 | Needham | Reiterates | Buy | — |
| 17 Mar 2026 | Stifel | Maintains | Buy | — |
| 12 Nov 2025 | Canaccord Genuity | Maintains | Hold | — |
| 21 Aug 2025 | Canaccord Genuity | Maintains | Hold | — |
| 12 May 2025 | Canaccord Genuity | Downgrade | Hold | — |
| 9 May 2025 | Needham | Maintains | Buy | — |
| 8 Apr 2025 | Needham | Reiterates | Buy | — |
| 28 Feb 2025 | Needham | Maintains | Buy | — |
| 28 Feb 2025 | Stifel | Maintains | Buy | — |
| 16 Jan 2025 | Needham | Reiterates | Buy | — |
| 20 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 20 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DCGO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, DocGo, Inc. returned −74.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 61% of US stocks
Cheaper than 96% of US stocks
Cheaper than 88% of US stocks
Cheaper than 63% of US stocks
Higher than 17% of US stocks
Higher than 28% of US stocks
Higher than 35% of US stocks
Higher than 20% of US stocks
Higher than 8% of US stocks
Higher than 12% of US stocks
Higher than 19% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
DocGo, Inc. has a market value of $25.0M and an enterprise value of $2.5M.
Revenue in the twelve months to 30 June 2026: $294.7M. The latest quarter shrank 8.7% year on year.
Net income over the same four quarters: −$206.7M, a −70.1% net margin.
Diluted earnings per share, trailing twelve months: $−1.96.
Free cash flow in the twelve months to 30 June 2026: −$28.6M.
DocGo, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 8.5×; forward P/E: 6.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
DocGo, Inc. employs 2,537 people — $116K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own DocGo, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
DocGo announced that it will report third-quarter 2026 results on Monday, November 9, 2026. Management will host a conference call and webcast at 5:00 p.m. ET that day.
Why it matters — DCGO watchers can note when the company plans to release its quarterly results and provide an accompanying call and webcast.
DocGo Inc. discussed its pending acquisition of Hicuity Health and related financial projections in a transcript published by Seeking Alpha. The item covers the company's outlook regarding that transaction.
Why it matters — A DCGO watcher would care because the Hicuity Health acquisition and its financial projections are likely to affect the company's near-term growth and results.
DocGo announced that CEO Lee Bienstock and senior Hicuity Health executives will host a webinar on September 29th at 11:00 a.m. ET to outline the vision and details of DocGo's pending acquisition of Hicuity Health, a provider of tele-ICU, virtual nursing, telemetry monitoring and virtual care services.
Why it matters — DCGO watchers will be able to learn more about the strategic rationale and specifics of the pending Hicuity Health acquisition directly from company leadership.
DocGo Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation is now available via Seeking Alpha. The item reports the conference appearance and transcript availability without detailing specific remarks.
Why it matters — A DCGO watcher would care because investor exposure at a major healthcare conference and the release of its transcript offer an opportunity to review management's messaging to the financial community.
DocGo announced that CEO Lee Bienstock will participate in one-on-one meetings and deliver a fireside presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th. A webcast of the event will be made available on the investor relations section of DocGo's website.
Why it matters — A DCGO watcher would care because the CEO's presentation at a major healthcare investment conference offers investors an opportunity to hear directly from management about the company.
The 5 Wall Street analysts covering DocGo, Inc. have a median 12-month price target of $1.75, with estimates ranging from $1 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering DocGo, Inc., 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DocGo, Inc. 41 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, DocGo, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +571.6% from the last close, and Ticker Nerd's factor model ranks DocGo, Inc. 41 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering DocGo, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $3 over the next 12 months.
DocGo, Inc. returned -74.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
DocGo Inc. is a healthcare services company that provides mobile health and medical transportation solutions for patients, hospitals, health systems, insurers, employers, and public-sector organizations.
The most recent item we track (Business Wire, 3 Nov 2026): "DocGo to Announce Third Quarter 2026 Results on Monday, November 9, 2026". DocGo announced that it will report third-quarter 2026 results on Monday, November 9, 2026. Management will host a conference call and webcast at 5:00 p.m. ET that day.
DocGo Inc. is a healthcare services company that provides mobile health and medical transportation solutions for patients, hospitals, health systems, insurers, employers, and public-sector organizations. DocGo Inc. combines proprietary technology with skilled clinicians to deliver care through mobile and virtual channels, including in-home and on-site urgent care, diagnostic testing, vaccinations, monitoring, care management, and remote patient support. Its transportation services include emergency response and non-emergency medical transport such as ambulance and wheelchair services. The company also supports event-based healthcare coverage and mobile clinical programs designed to extend care beyond traditional facilities. Headquartered in New York, DocGo Inc. plays a role in the shift toward more accessible, decentralized care delivery across the United States and the United Kingdom.
CEO Mr. Lee Bienstock · 2,537 employees · United States · https://docgo.com
